Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Metrics to compare | JANX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJANXPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.0x | −1.3x | −0.6x | |
PEG Ratio | 0.13 | −0.05 | 0.00 | |
Price/Book | 1.4x | 1.7x | 2.6x | |
Price / LTM Sales | 3,138.8x | 8.3x | 3.3x | |
Upside (Analyst Target) | 229.7% | 283.4% | 39.1% | |
Fair Value Upside | Unlock | 32.6% | 5.4% | Unlock |